Skip to main content
Premium Trial:

Request an Annual Quote

Sirna to Manufacture Archemix Drug Candidate

NEW YORK, Oct. 27 (GenomeWeb News) - Sirna Therapeutics has signed on to manufacture for Archemix the antithrombin aptamer ARC183, the companies said today.

 

ARC183 is Archemix's first drug development candidate and is being tested for use as an anti-coagulant/anti-thrombotic in coronary artery bypass graft surgery. Under their arrangement, Sirna will make and supply Archemix with the agent for use in its development efforts through phase IIa clinical trials.

 

"This collaboration is consistent with our strategy of forming process development and manufacturing agreements ... to generate revenues and maintain our leadership in the nucleic acid chemistry field," Sirna president and CEO Howard Robin said in a statement.

 

Specific terms of the deal were not disclosed.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.